Esperion Therapeutics ESPR Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Esperion Therapeutics (ESPR) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $26.69M in Q4 2025.
- How has Esperion Therapeutics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost changed year-over-year?
- Esperion Therapeutics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost increased by 2.4% year-over-year, from $26.06M to $26.69M.
- What is the long-term trend for Esperion Therapeutics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Over 5 years (2020 to 2025), Esperion Therapeutics's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost has grown at a 4.5% compound annual growth rate (CAGR), from $21.45M to $26.69M.